Expert Q&A: Is Standardization The Bottleneck Or Breakthrough To Building Scalable And Cost-Effective CGT Programs?

This expert Q&A explores whether standardization is a barrier or a catalyst for building scalable, cost‑effective CGT programs. The contributors emphasize that early scientific success can be misleading if the operational foundation isn’t strong enough to support later‑stage demands. They highlight a recurring industry blind spot: assuming the science alone will carry a program forward. Instead, they stress the importance of designing for manufacturability, comparability, and regulatory readiness from the outset, noting that early wins often fail to translate into long‑term feasibility without rigorous process control.

The discussion underscores that many late‑stage setbacks stem from early decisions that outpace manufacturing maturity, analytics, and documentation. Experts advise involving manufacturing and quality leadership early in development to prevent costly resets, delays, or regulatory hurdles. A robust, future‑focused operational strategy, they argue, is essential for maintaining continuity, managing risk, and ultimately ensuring therapies can scale reliably and reach patients.